| Popis: |
Bleeding disorders are common in patients with cancer. The vasculature, platelet number and function and coagulation system may all be adversely affected by the malignancy and/or its treatments. While the cause of bleeding may be straightforward in patients with anatomic lesions or chemotherapy-induced thrombocytopenia, more often a careful clinical assessment, including a thorough understanding of the underlying cancer and its therapy, judicious use of laboratory studies including specialized coagulation assays, examination of the peripheral blood smear, and occasionally invasive procedures such as a bone marrow biopsy, is required. Treatment is highly dependent on the underlying etiology and may involve the use of local therapies, platelet or plasma product transfusion, factor replacement, antifibrinolytic agents, and/or treatment of the underlying malignancy. |
